Unlock the power of peptides and proteins - Explore and harness the potential of affordable peptides and proteins with our disruptive bioprocesses for discovery, optimization and production.
Numaferm has invented the first high-expression platform dedicated to peptides and proteins, Numatech. With Numatech the power of biosynthesis becomes accessible independent of the target’s length, physicochemical properties and functionalities.
Numatech serves as a unique high titer expression platform enabling material supply in a short timeframe (weeks), at needed scales (mg to ton scale), reduced costs (> 90%) and highest qualities (> 99%). Evolved by nature, discovered by leading scientists, applied by Numaferm. We ensure success with the highest service standards
Numaferm is an ISO 9001:2015 certified company dedicated to quality and customer satisfaction. With a track record of > 200 successful produced peptides, Numaferm has become a trusted partner in the industry.
Numaferm’s cutting edge technologies are made for the discovery and production of peptides and proteins.
Lead Discovery Service: Discover unique and superior lead candidates
Numascreen™ phage display libraries are first in market high-diversity libraries with over 1 billion for peptides > 20 aa. Using Numascreen we discover and optimize your high-affinity binders with unique properties.
Cell line & Process Development Programs: Produce high-quality peptides quickly, at scale and with reduced costs
Numatech™ serves as a unique high-titer expression platform enabling material supply in a short timeframe, at needed scales, reduced costs and the highest qualities.
Industry-grade processes and access to broad partner network
The commercial and/or GMP production is realized by our established partner network of well-known CMO companies. Our production processes are industry-grade and ready to be transferred to production plants.
Immerse yourself in the world of Numatech - Numaswitch:
The production of peptides as active pharmaceutical ingredients (APIs) by recombinant technologies is of emerging interest.
A reliable production platform, however, is still missing due the inherent characteristics of peptides such as proteolytic sensitivity, aggregation and cytotoxicity.
We have developed a new technology named Numaswitch solving present limitations. Numaswitch was successfully employed for the production of diverse peptides and small proteins varying in length, physicochemical and functional characteristics, including Teriparatide, Linaclotide, human β-amyloid and Serum amyloid A3.
Additionally, the potential of Numaswitch for a cost-efficient commercial production is demonstrated yielding > 2 g Teriparatide per liter fermentation broth in a quality meeting API standard.
• Competitive production processes for generics and biosimilars, i.e. PTH(1-34), PTH(1-84), Liraglutide, Semaglutide.Further reading